{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:08:57Z","timestamp":1779145737322,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K08DK106489"],"award-info":[{"award-number":["K08DK106489"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK120946"],"award-info":[{"award-number":["R03DK120946"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 T32 DK7740-22"],"award-info":[{"award-number":["5 T32 DK7740-22"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) is effective for treating midgut neuroendocrine tumors (NETs); however, incorporation of PRRT into routine practice in the U.S. is not well studied. Herein we analyze the first year of PRRT implementation to determine tolerance of PRRT and factors that increase risk of PRRT discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Medical records were reviewed and data were abstracted on all patients with NETs scheduled for PRRT during the first year of PRRT implementation at a U.S. NET referral center (August 2018 through July 2019). Logistic regression was used to identify factors associated with PRRT discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-five patients (56% male) were scheduled for PRRT over the study period. The most common primary NET location was small bowel (47%), followed by pancreas (26%), and 84% of the NETs were World Health Organization grade 1 or 2. The cohort was heavily pretreated with somatostatin analog (SSA) therapy (98%), non-SSA systemic therapy (64%), primary tumor resection (73%), and liver-directed therapy (55%). At the time of analysis, 52 patients completed at least one PRRT treatment. Toxicities including bone marrow suppression and liver function test (LFT) abnormalities were comparable to prior publications. Eleven patients (21%) prematurely discontinued PRRT because of toxicity or an adverse event. Pretreatment LFT abnormality was associated with increased risk of PRRT cancellation (odds ratio: 12; 95% confidence interval: 2.59\u201355.54; p &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PRRT can be administered to a diverse NET population at a U.S. NET referral center. Baseline liver function test abnormality increases the likelihood of PRRT discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) can be successfully implemented at a U.S. neuroendocrine tumor (NET) referral center in a NET population that is diverse in tumor location, grade, and prior treatment history. Toxicity and adverse effects of PRRT are comparable to prior reports; however, 21% of individuals prematurely discontinued PRRT. Patients with baseline liver function test abnormalities were more likely to discontinue PRRT than patients with normal liver function tests, which should be taken into consideration when selecting treatment options for NETs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0743","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:10:38Z","timestamp":1583496638000},"page":"572-578","source":"Crossref","is-referenced-by-count":10,"title":["Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort"],"prefix":"10.1093","volume":"25","author":[{"given":"Jason M.","family":"Heckert","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit T.","family":"Kipnis","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shria","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Botterbusch","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Alderson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonita","family":"Bennett","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Creamer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Eads","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Soulen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Pryma","sequence":"additional","affiliation":[{"name":"Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Mankoff","sequence":"additional","affiliation":[{"name":"Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Metz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryson W.","family":"Katona","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"2021122510434941200_onco13278-bib-0001","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122510434941200_onco13278-bib-0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122510434941200_onco13278-bib-0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000441897","article-title":"Changes in epidemiology of NETs","volume":"104","author":"Huguet","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2021122510434941200_onco13278-bib-0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"2021122510434941200_onco13278-bib-0005","article-title":"Current best practice in the management of neuroendocrine tumors","volume":"10","author":"Tsoli","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2021122510434941200_onco13278-bib-0006","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/MPA.0000000000000919","article-title":"Efficacy of peptide receptor radionuclide therapy in a United States-based cohort of metastatic neuroendocrine tumor patients: Single-institution retrospective analysis","volume":"46","author":"Katona","year":"2017","journal-title":"Pancreas"},{"key":"2021122510434941200_onco13278-bib-0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11912-017-0567-8","article-title":"Radionuclide therapy for neuroendocrine tumors","volume":"19","author":"Cives","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2021122510434941200_onco13278-bib-0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12149-017-1163-6","article-title":"Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y\/177 Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: A 10-year study","volume":"31","author":"Kunikowska","year":"2017","journal-title":"Ann Nucl Med"},{"key":"2021122510434941200_onco13278-bib-0009","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: Six years' assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2021122510434941200_onco13278-bib-0010","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s00259-015-3155-x","article-title":"The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: A meta-analysis","volume":"42","author":"Kim","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510434941200_onco13278-bib-0011","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","article-title":"Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine","volume":"42","author":"Sabet","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510434941200_onco13278-bib-0012","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","article-title":"177 Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: Results from a phase II study","volume":"41","author":"Paganelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510434941200_onco13278-bib-0013","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510434941200_onco13278-bib-0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"key":"2021122510434941200_onco13278-bib-0015","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122510434941200_onco13278-bib-0016","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90YDOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510434941200_onco13278-bib-0017","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"Van der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510434941200_onco13278-bib-0018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): Feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510434941200_onco13278-bib-0019","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122510434941200_onco13278-bib-0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","article-title":"Peptide receptor radionuclide therapy\u2013induced hepatotoxicity in patients with metastatic neuroendocrine tumors","volume":"40","author":"Riff","year":"2015","journal-title":"Clin Nucl Med"},{"key":"2021122510434941200_onco13278-bib-0021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/MPA.0000000000000734","article-title":"Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors","volume":"46","author":"Sharma","year":"2017","journal-title":"Pancreas"},{"key":"2021122510434941200_onco13278-bib-0022","author":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","year":"2010"},{"key":"2021122510434941200_onco13278-bib-0023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/ERC-18-0424","article-title":"Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study","volume":"26","author":"Carlsen","year":"2019","journal-title":"Endocr Relat Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0743","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/572\/41920451\/oncolo_25_7_572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/572\/41920451\/oncolo_25_7_572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:44:39Z","timestamp":1640429079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/7\/572\/6443632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,3,6]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0743","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,3,6]]}}}